ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...
A landmark trial has confirmed real-time continuous glucose monitoring (CGM) improves blood sugar control in type 2 diabetes, while new wearable sensors promise broader, continuous biomarker tracking.
†The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and ...
Collaboration brings together FreeStyle Libre ® Systems, the world's leading continuous glucose monitoring technology (CGM) 1 with Epic, a healthcare software company, to streamline access to CGM data ...